Floatz logo

Cediranib

Anaplastic Large Cell Lymphoma, ALK-Positive

University of WashingtonSmall moleculePhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Anaplastic Large Cell Lymphoma, ALK-Positive cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Mingzhi Zhang
Phase 4BB
Crizotinib
Mingzhi Zhang
Phase 4BB
Inno-206
Huiqiang Huang
Phase 2BB
Cyclophosphamide
Huiqiang Huang
Phase 2BB
DEXAMETHASONE
Huiqiang Huang
Phase 2BB

View all 19 →

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →